Document Detail

Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension.
MedLine Citation:
PMID:  18221609     Owner:  NLM     Status:  In-Data-Review    
Portal hypertensive gastropathy (PHG) and gastric antral vascular ectasia (GAVE) are two distinct gastric mucosal lesions that may cause acute and/or chronic upper gastrointestinal hemorrhage in patients with cirrhosis. Whereas PHG is associated with portal hypertension, GAVE may present in patients without portal hypertension or liver disease. Diagnosis is made upon visualization of the characteristic lesions with upper gastrointestinal endoscopy, although the differential may be difficult at times. PHG is characterized endoscopically by a mosaic pattern with or without red signs and a proximal distribution. PHG mainly causes chronic blood loss and anemia in patients with cirrhosis but also can cause acute hemorrhage. First-line therapy for chronic hemorrhage from PHG is a nonselective beta-blocker (propranolol or nadolol) and iron supplementation. If bleeding/anemia are not controlled with these measures and the patient is transfusion-dependent, shunt therapy (transjugular intrahepatic portosystemic shunt or shunt surgery) should be considered. Management of acute bleeding from PHG, an infrequent event, should be accomplished with a vasoactive drug, somatostatin (or its analogues) or terlipressin. If bleeding responds, the patient must be switched to a nonselective beta-blocker. Shunt therapy should be considered in patients who rebleed or continue to bleed despite adequate beta-blocker therapy. GAVE is less common than PHG. It is characterized by red spots without a background mosaic pattern, typically in the gastric antrum. When lesions have a linear distribution, the lesion is called "watermelon stomach." GAVE is a cause of chronic gastrointestinal bleeding and anemia in patients with cirrhosis. If lesions are localized, first-line therapy is argon plasma coagulation. In more diffuse lesions, therapy with argon plasma coagulation is more complicated. Preliminary data suggest that cryotherapy may be a reasonable option for diffuse GAVE lesions. Neither beta-blockers nor TIPS reduces the bleeding risk in patients with GAVE and thus should not be used in this setting.
Cristina Ripoll; Guadalupe Garcia-Tsao
Related Documents :
9149189 - Clinical and endoscopic risk factors in the mallory-weiss syndrome.
18379899 - The coagulopathy of acute liver failure and implications for intracranial pressure moni...
7672549 - Prospective validation of the baylor bleeding score for predicting the likelihood of re...
9638459 - Intraoperative enteroscopy in obscure gastrointestinal hemorrhage.
8210979 - Same-day upper and lower endoscopy in patients with occult bleeding, melena, hematochez...
14750939 - Iliopsoas haemorrhage in patients with bleeding disorders--experience from one centre.
9355669 - Juvenile chronic arthritis--bone mineral density in relation to corticosteroid therapy.
3120379 - Distant procurement of organs for clinical heart-lung transplantation using a single fl...
20954979 - Catheter access for hemodialysis defines higher mortality in late-presenting dialysis p...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in gastroenterology     Volume:  10     ISSN:  1092-8472     ISO Abbreviation:  Curr Treat Options Gastroenterol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815941     Medline TA:  Curr Treat Options Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  483-94     Citation Subset:  -    
Guadalupe Garcia-Tsao, MD Digestive Diseases Section, Yale University School of Medicine, 333 Cedar Street--1080 LMP, New Haven, CT 06510, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of Hepatitis B e Antigen-negative Patients.
Next Document:  The Multiple Facets of ABCB4 (MDR3) Deficiency.